Log In
BCIQ
Print this Print this
 

CK-101, RX518

  Manage Alerts
Collapse Summary General Information
Company Suzhou NeuPharma Co. Ltd.
DescriptionThird-generation covalent inhibitor of EGFR-activating mutations and the T790M EGFR resistance mutation
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerCheckpoint Therapeutics Inc.;
Fortress Biotech Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today